Trump Administration Poised to Extend Telemedicine Prescribing of Controlled Substances

The Trump administration is expected to extend a temporary rule allowing healthcare providers to prescribe medications for conditions like ADHD and opioid use disorder via telemedicine, continuing a policy initially enacted during the COVID-19 pandemic.

Under the existing rules, first implemented by the Drug Enforcement Administration in March 2020, patients can receive prescriptions for controlled substances such as Ritalin, Adderall, and buprenorphine without an initial in-person examination. This extension would be the fourth time the federal government has renewed these flexibilities while a permanent regulatory framework is developed. A notice posted on a White House budget website indicates the administration anticipates the need for at least another year of temporary rules.

The continuation of these policies has spurred growth in telehealth companies specializing in remote prescribing, but has also drawn criticism from those concerned about potential misuse or addiction. However, some research suggests that telehealth patients receiving ADHD medications do not experience higher rates of addiction compared to those seen in traditional office visits. The Biden administration previously attempted to reimpose some restrictions in 2023, facing significant opposition, and proposed a special registry for telemedicine prescribers in January, but the proposal came too late to finalize before the change in administration. The Drug Enforcement Administration plays a key role in regulating these prescriptions.

During his confirmation hearings, DEA Administrator Terry Cole stated he would give “careful consideration” to maintaining access to telehealth services for substance use disorders, as reported by Senator Sheldon Whitehouse. This extension comes as telehealth services more broadly have faced challenges, including a decline in Medicare-covered visits following a recent government funding lapse, highlighting the ongoing debate surrounding the future of remote healthcare access. Health literacy is a key factor in ensuring patients understand their treatment options.

Officials have indicated that finalizing long-term regulations for telemedicine prescribing remains a priority, with ongoing discussions about differentiating between various drug schedules and how to best regulate stimulant medications for ADHD.